

CJC-1295/Ipamorelin

ACTIVE CJC-1295 + ipamorelin

FORM Form and strength confirmed only during clinician review



01 / TREATMENT OVERVIEW

The clinical and commercial fit

Potential support for deeper sleep, exercise recovery, body-composition goals, and a more consistent sense of vitality. Aims to stimulate the patient's own pulsatile growth-hormone pathway rather than provide growth hormone directly. A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.

WHY PRACTITIONERS CONSIDER IT

Potential support for deeper sleep, exercise recovery, body-composition goals, and a more consistent sense of vitality.

A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.

02 / TREATMENT FEATURES

01

Administration

- Catalog format: Form and strength confirmed only during clinician review. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.

02

Typical frequency

- Frequency is individualized around the exact formulation, patient goals, tolerability, and monitoring plan.

03

Expected duration

- No controlled study defines a treatment course or proves durable body-composition, sleep, or recovery outcomes.

04

Practical advantages

- A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.

Why suitable patients may consider it

POTENTIAL PATIENT BENEFITS

What suitable patients may value

- Potential support for deeper sleep, exercise recovery, body-composition goals, and a more consistent sense of vitality.
- Aims to stimulate the patient’s own pulsatile growth-hormone pathway rather than provide growth hormone directly.
- May appeal to adults seeking a clinician-monitored recovery or healthy-aging program with measurable hormone and metabolic follow-up.

ADDITIONAL PATIENT VALUE

Experience and care goals

- A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.
- Can be paired with sleep, nutrition, resistance-training, body-composition, glucose, and IGF-1 tracking.

The peptides can raise growth-hormone signals in early human research, but patient-centered wellness outcomes for the blend remain uncertain. Benefits vary and are not guaranteed.

Who is most likely to be a fit

BEST-FIT PATIENT

Qualification profile

- A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
- A patient willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

CLINICAL CONTEXT

Qualification notes

- A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.
- Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

05 / POTENTIAL SIDE EFFECTS

The safety information patients need

COMMON OR TEMPORARY

Expected tolerability issues

- Human blend frequencies are unknown. Potential effects include injection reactions, headache, flushing, dizziness, hunger, water retention, joint discomfort, tingling, and sleep or dream changes.

SERIOUS OR IMPORTANT

Risks that change the decision

- Growth-hormone and IGF-1 elevation may worsen glucose control, edema, carpal-tunnel symptoms, and untreated sleep apnea; long-term cardiovascular and cancer safety are not established.
- Unapproved injection adds contamination, concentration, and sterility risk.

06 / CONTRAINDICATIONS

Who may not be a suitable candidate

AVOID OR USE SPECIALIST INPUT

Suitability limits

- Active malignancy, pregnancy or breastfeeding, uncontrolled diabetes, severe untreated sleep apnea, proliferative eye disease, acute critical illness, or unverified product identity.
- Use in children or adolescents for height, performance, or wellness outside specialist pediatric endocrine care.

Side effects and suitability notes are not exhaustive. The exact product, patient history, dosing, monitoring, and emergency guidance require review by an appropriately licensed clinician.

What to check before treatment

BEFORE TREATMENT

Screening checklist

- Clarify the CJC molecule and formulation; assess sleep, apnea risk, blood pressure, glucose status, edema, neurologic symptoms, pituitary history, cancer history, medicines, pregnancy status, and baseline IGF-1 when medically appropriate.
- Set a clinically meaningful outcome and stopping rule rather than treating a hormone rise as proof of benefit.

ESCALATION

When to refer

- Suspected pituitary disease, abnormal IGF-1, progressive headache or visual symptoms, marked edema, worsening glucose, or sleep-apnea symptoms requires endocrinology or appropriate medical assessment.

Screening and referral decisions are patient-specific. This summary does not replace diagnosis, prescribing information, informed consent, or local clinical requirements.

What the strongest public sources support

CURRENT STATUS

Investigational for wellness, body composition, sleep, and recovery; the combination has no established approved indication.

- Two short randomized CJC-1295 studies showed multi-day GH and IGF-1 increases in healthy adults. An ipamorelin dose-escalation study showed a brief GH peak. Neither tested the commercial combination or meaningful long-term clinical outcomes.

KEY CLINICAL SOURCES

Primary or official source: CJC-1295 randomized healthy-adult trials, 2006

Primary or official source: Ipamorelin pharmacokinetic study in healthy volunteers, 1999

Primary or official source: Clinical review of unapproved injectable peptides, 2026

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

How the research maps to this exact product

Small human studies show each peptide can raise growth hormone. No good trial shows the pair improves sleep, muscle, fat, or recovery.

STUDY 01 Primary human finding CJC-1295 - two randomized double-blind dose-escalation studies in healthy adults, lasting 28 and 49 days. Subcutaneous doses raised GH 2-10 fold and IGF-1 1.5-3 fold for days; no serious reactions reported. It measured hormones, not wellness outcomes.	STUDY 02 Supporting context Ipamorelin - dose-escalation infusion study; eight healthy men per dose level. It caused a brief GH peak around 0.67 hours; half-life about 2 hours. It did not test long-term benefit.
---	--

Research on a related ingredient, route, dose, or population may not predict the outcome of the exact product offered. Potential benefits remain patient-specific and are not guaranteed.

What people report and how the evidence matches

REAL-WORLD REPORTS

What people describe

- About 10 detailed accounts were sampled. Deeper sleep and recovery were the most common claimed benefits after 1-4 weeks. Several saw no body change. Water retention, tingling, hunger, headache, vivid dreams, injection reactions, and higher glucose were recurring complaints.

TIMING AND MATCH

When changes are reported

- Sleep claims: days to 4 weeks. Body changes: often 2-4 months, if reported.
- Separate short studies do not prove that the combined catalog product works.

SOURCE NOTES

Direct links are included for verification. Public personal accounts are unverified and cannot show how common an outcome is. Evidence for one ingredient, route, or dose does not automatically validate a different compounded or blended product.

Product listing: Lennox catalog page; accessed Aug 26, 2026

User-reported evidence: Mixed peptide experiences, Reddit 2025

PRACTICE NOTE

This report supports informed discussion; it does not tell anyone to start, stop, or dose a treatment. Verify the exact ingredients, concentration, route, dispensing source, storage, beyond-use date, contraindications, and monitoring plan.